SHA: 600196

Explore the latest insights on SHA: 600196 and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of SHA: 600196’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

European Commission Approves AbbVie’s RINVOQ (Upadacitinib) for Juvenile Idiopathic Arthritis – Ninth EU Indication for the JAK Inhibitor

AbbVie Inc. (NYSE: ABBV) announced that the European Commission (EC) has approved RINVOQ (upadacitinib) for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients aged 2 years and…

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.